RxDoctor Payments DataLook up a doctor →

Olinda Spencer, MD

Neurology · Little River, SCNPI 1487072823

Payments from drug & device makers

$44,094in general payments, 2019–2025

Across 725 payments — averaging $60.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$15K
  • Biohaven Pharmaceuticals, Inc.$12K
  • Biohaven Pharmaceutical Holding Company Ltd.$5K
  • AbbVie$1K
  • Novartis$851
  • UCB, Inc.$629
  • plus $9K from 53 others

What the payments were for

  • Consulting fees$1500%
  • Speaking & faculty fees$27,96363%
  • Travel & lodging$2951%
  • Food & beverage$15,27035%
  • Education$4161%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.203$15,049
Biohaven Pharmaceuticals, Inc.22$12,442
Biohaven Pharmaceutical Holding Company Ltd.8$5,165
AbbVie(2 entities)120$1,412
Novartis38$851
UCB, Inc.25$629
Acadia Pharmaceuticals Inc22$589
AstraZeneca13$542
Biogen15$524
Medtronic5$475
EMD Serono, Inc.24$458
Amgen(2 entities)15$429
Lundbeck LLC16$335
Lilly USA, LLC15$296
Sanofi13$289
MDD US Operations, LLC5$271
Averitas Pharma Inc.5$263
Bristol Myers Squibb12$228
Amneal Pharmaceuticals LLC7$200
TG Therapeutics, Inc.11$198
SK Life Science, Inc.8$195
Johnson & Johnson(2 entities)5$188
Acorda Therapeutics, Inc9$171
Foundation Medicine, Inc.1$165
Procept Biorobotics Corporation1$160
Eisai Inc.4$157
Supernus Pharmaceuticals, Inc.4$157
Davol Inc.1$151
Mallinckrodt Hospital Products Inc.6$151
Upsher-smith Laboratories LLC8$140
Kyowa Kirin, Inc.9$138
Pfizer8$138
E.r. Squibb & Sons, L.L.C.3$128
Alnylam Pharmaceuticals Inc.6$127
Neurocrine Biosciences, Inc.5$121
Avanir Pharmaceuticals, Inc.6$116
Aquestive Therapeutics, Inc.6$110
Stryker1$103
Adamas Pharmaceuticals, Inc.6$100
Boston Scientific1$85
Otsuka America Pharmaceutical, Inc.4$83
Livanova USA, Inc.4$69
Tanabe Pharma America, Inc.3$47
Baxter Healthcare1$46
Axsome Therapeutics, Inc.2$44
Genentech USA, Inc.2$44
Currax Pharmaceuticals LLC3$38
Neurelis, Inc.2$35
Ceribell, Inc.1$32
Merz Pharmaceuticals, LLC1$28
Zyla Life Sciences, Inc.2$26
Sumitomo Pharma America, Inc.1$25
Mallinckrodt Enterprises LLC1$24
Argenx US, Inc.1$24
Sunovion Pharmaceuticals Inc.1$22
Jazz Pharmaceuticals Inc.1$22
Grifols USA, LLC1$16
Cala Health, Inc.1$15
Greenwich Biosciences, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,094 in reported general payments places this provider in the 85th percentile of 270 neurology providers in South Carolina.

See all neurology providers in South Carolina

Medicare billing

Part B allowed, 2024
$499,158
Medicare patients
1,103
Services billed
80,198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PanzygaImmun Glob G(Igg)-Ifas/Glycine18$405,245
Kesimpta PenOfatumumab40$363,392
EnspryngSatralizumab-Mwge13$227,756
CopaxoneGlatiramer Acetate15$137,911
BetaseronInterferon Beta-1b14$136,539
Nurtec OdtRimegepant Sulfate59$77,328
Aimovig AutoinjectorErenumab-Aooe65$66,707
UbrelvyUbrogepant45$62,438
NuplazidPimavanserin Tartrate11$54,962
QuliptaAtogepant34$40,651
Emgality SyringeGalcanezumab-Gnlm20$36,263
RytaryCarbidopa/Levodopa13$26,756
Emgality PenGalcanezumab-Gnlm24$23,013
Ajovy AutoinjectorFremanezumab-Vfrm15$17,038
VimpatLacosamide16$17,021

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPanzyga, Nurtec Odt$138$482,57477 claims
Genentech USA, Inc.Enspryng$44$227,75613 claims
Teva Pharmaceuticals USA, Inc.Copaxone$15,049$137,91115 claims
AbbVieUbrelvy, Qulipta, Namzaric$1,412$115,23293 claims
Acadia Pharmaceuticals IncNuplazid$589$54,96211 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$200$30,41544 claims
UCB, Inc.Vimpat$629$17,02116 claims
Lilly USA, LLCReyvow$296$12,13617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 270 neurology providers in South Carolina.

Other neurology in Little River

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →